Report Highlights

U.S. Arteriovenous Malformation Market: Market Overview

The U.S. arteriovenous malformation market encompasses diagnostic imaging, interventional neurosurgery, stereotactic radiosurgery, and endovascular embolization products and services used to detect and treat cerebral and spinal AVMs. Valued at USD 1.42 billion in 2024, the market is primarily structured around tertiary neuroscience centers, academic medical centers, and a concentrated network of specialized AVM treatment programs at institutions such as Barrow Neurological Institute, Johns Hopkins Hospital, and UCSF Medical Center. The Centers for Medicare and Medicaid Services functions as the dominant payer for AVM-related procedures, given that the condition disproportionately affects patients over 50 years of age who present with hemorrhagic stroke.

Government policy has been the principal force shaping market structure through Medicare reimbursement schedules and the NIH-funded A Randomized Trial of Unruptured Brain Arteriovenous Malformations (ARUBA) study, whose findings directly influenced clinical guideline development by the American Stroke Association. Private sector leadership has emerged in device innovation — particularly in liquid embolic agents such as Medtronic's Onyx and microcatheter systems — while hospital systems have led in establishing dedicated AVM treatment programs funded partly through CMS case-mix index weighting that rewards complex neurovascular case volume under the Inpatient Prospective Payment System (IPPS).

Policy-Driven Growth in U.S. AVM Treatment

Three policy mechanisms are directly accelerating the U.S. AVM market. First, the Consolidated Appropriations Act of 2023 extended telehealth flexibilities through 2024 and enabled remote neurology consultations for AVM diagnosis, expanding the referral pipeline from rural and underserved regions into tertiary AVM centers. CMS billing codes G0508 and G0509 now support reimbursable critical care telehealth consults at rates of USD 261 and USD 195 per encounter respectively, channeling previously undiagnosed AVM patients into the formal treatment pathway and expanding the addressable market by an estimated 12% in non-metropolitan geographies.

Second, the FDA's 510(k) clearance of next-generation embolic agents under the De Novo pathway has accelerated device market expansion by reducing time-to-market for AVM-specific endovascular tools. Third, the NIH National Institute of Neurological Disorders and Stroke (NINDS) awarded USD 47 million in AVM-related research grants between 2021 and 2024 under the Brain Research Through Advancing Innovative Neurotechnologies (BRAIN) Initiative, directly funding translational research that feeds commercial licensing pipelines. Each funded discovery that reaches clinical trial stage creates incremental demand for imaging, navigation, and embolization equipment at participating research hospitals, sustaining institutional capital expenditure cycles throughout the forecast period.

Regulatory Barriers and Compliance Costs

The FDA's Center for Devices and Radiological Health (CDRH) administers the premarket approval (PMA) pathway for Class III neurovascular devices, which governs most advanced AVM treatment systems. Average PMA approval timelines run 180 to 360 days for devices with clinical data, and full PMA review cycles with panel review can extend beyond two years for novel embolic compounds. These timelines impose significant carrying costs on device manufacturers, with regulatory compliance spending for a single PMA submission estimated between USD 5 million and USD 12 million, including clinical trial execution, Good Manufacturing Practice (GMP) facility audits, and post-approval study commitments required under 21 CFR Part 814.

Local content and institutional credentialing rules create an additional compliance layer. The Joint Commission's Advanced Certification in Comprehensive Stroke Centers (CSC) requires AVM treatment programs to meet specific volume thresholds, neurosurgical staffing ratios, and outcome reporting obligations under its Disease-Specific Care Certification Standards. Hospitals that fail to maintain CSC accreditation risk exclusion from value-based care contracts administered through CMS's Merit-based Incentive Payment System (MIPS), which directly affects reimbursement rates. Smaller regional hospitals face disproportionate compliance costs estimated at USD 800,000 to USD 1.5 million annually for maintaining the staffing and reporting infrastructure required to sustain Joint Commission AVM-related certification.

Policy-Created Opportunities in the U.S. AVM Market

The CMS Hospital Outpatient Prospective Payment System (HOPPS) reclassification of stereotactic radiosurgery procedures under Ambulatory Payment Classification (APC) 5627 has created a clear commercial opportunity for freestanding radiosurgery centers treating unruptured AVMs on an outpatient basis. This reclassification, effective January 2024, raised reimbursement for cranial SRS by approximately 4.3%, incentivizing capital investment in Gamma Knife and CyberKnife systems outside hospital campuses. Varian Medical Systems and Accuray are the primary beneficiaries, as freestanding oncology and neurology centers expand AVM treatment capacity to capture newly reimbursable outpatient volume without incurring the overhead of inpatient neurosurgery departments.

A second major opportunity is created by the FDA's Breakthrough Device Program, which currently has AVM-related digital health applications under review. Artificial intelligence-based AVM grading and treatment planning tools — such as those developed by Brainomix and Aidoc — are positioned to receive expedited review under the FDA's AI/ML-Based Software as a Medical Device (SaMD) Action Plan, published in 2021. If cleared, these tools qualify for Category III CPT codes, enabling reimbursement pathways that did not exist before 2023. Payers including UnitedHealthcare and Aetna have issued preliminary positive coverage determinations for AI-assisted neurovascular imaging, signaling commercial adoption ahead of full federal reimbursement codification.

Market at a Glance

Leading Market Participants

• Medtronic plc
• Elekta AB
• Accuray Incorporated
• Varian Medical Systems (Siemens Healthineers)
• Stryker Corporation
• Johnson and Johnson MedTech (Cerenovus)
• MicroVention (Terumo)
• Penumbra Inc.
• Integra LifeSciences
• Brainlab AG

Regulatory and Policy Environment

The primary legislative framework governing the U.S. AVM market is the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device Amendments of 1976 and subsequently by the FDA Safety and Innovation Act (FDASIA) of 2012 and the 21st Century Cures Act of 2016. The 21st Century Cures Act specifically created the Breakthrough Device Program administered by CDRH, which has materially shortened review timelines for AVM-adjacent neurovascular devices. CMS governs reimbursement under 42 CFR Part 419 for outpatient AVM procedures and 42 CFR Part 412 for inpatient neurosurgical DRG assignments, including DRG 023 and 024 covering craniotomy with and without major complications related to vascular malformations. Upcoming regulatory changes include the FDA's planned finalization of the AI/ML SaMD marketing submission guidance, expected in late 2025, which will establish binding premarket requirements for AVM treatment planning software.

Compared to regional peers, the U.S. regulatory framework is the most commercially permissive for AVM device entry, contrasting with the European Medical Device Regulation (EU MDR 2017/745), which imposes mandatory clinical data requirements for all Class IIb and III neurovascular devices regardless of predicate history. Canada's Health Products and Food Branch requires a separate device licence under the Medical Devices Regulations (SOR/98-282), while the U.S. 510(k) substantial equivalence pathway remains the fastest global route to market for AVM embolization catheters and coils. This regulatory asymmetry makes the U.S. the preferred launch market for all major AVM device manufacturers, reinforcing its position as the world's largest and most commercially advanced AVM treatment market through 2032.

Long-Term Policy Outlook for the U.S. AVM Market

By 2032, CMS is expected to complete its transition to fully risk-adjusted bundled payments for complex neurovascular conditions, including AVM, under an expanded Bundled Payments for Care Improvement Advanced (BPCI Advanced) model. If AVM treatment episodes are formally added to the BPCI Advanced track — an outcome supported by the American Association of Neurological Surgeons in its 2023 legislative priorities submission — providers will face fixed reimbursement envelopes covering the full care episode from diagnosis through 90-day post-procedure follow-up. This structural shift will accelerate consolidation among AVM treatment programs, favoring high-volume academic centers with established care pathways over community neurosurgery practices that cannot achieve the scale required to profit within bundled payment constraints.

Simultaneously, the FDA's Digital Health Center of Excellence is expected to issue final guidance on AVM-specific AI diagnostic tools by 2027, enabling Category I CPT code assignment and broad commercial reimbursement. This will commoditize initial AVM diagnosis and shift competitive differentiation entirely to treatment delivery platforms and outcomes data. Manufacturers that establish real-world evidence registries — such as the existing AVM registry coordinated through the NeuroPoint Alliance — will hold significant regulatory and commercial advantages, as CMS's Patient-Centered Outcomes Research Institute (PCORI) funding increasingly conditions reimbursement expansion on registry-linked outcomes data submitted under the agency's coverage with evidence development framework.